AFFYMAX AND TAKEDA ANNOUNCE FDA APPROVAL OF OMONTYS® (PEGINESATIDE) INJECTION FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD) IN ADULT PATIENTS ON DIALYSIS

28.03.2012

Palo Alto, Calif. – March 27, 2012, and Osaka, Japan – March 28, 2012 - Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia to be made available to the dialysis patient population in the United States.

Read more

 

Top of page

Takeda Pharma